GlassScriptPhysician profile
Martha Mooney
NPI 1902872203
$717.22
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $112 · 2021: $13.20 · 2023: $78.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $148.42 | 2019-2023 | Dificid, Zerbaxa, Recarbrio |
| Astellas Pharma US INC | $114.24 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $109.39 | 2019-2020 | |
| Philips North America LLC | $101.91 | 2019 | |
| Viiv Healthcare Company | $42.50 | 2019 | |
| Gilead Sciences, INC. | $38.70 | 2019-2020 | |
| Janssen Biotech, INC. | $37.14 | 2023 | Symtuza |
| Abbvie INC. | $26.14 | 2021-2023 | |
| Melinta Therapeutics, LLC | $23.02 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.78 | 2020 | |
| Advanced Respiratory, INC | $16.42 | 2019 | |
| Insmed, INC. | $15.79 | 2019 | |
| Allergan, INC. | $14.33 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.